443 related articles for article (PubMed ID: 30159416)
1. Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs.
Biersack B
Noncoding RNA Res; 2017 Mar; 2(1):1-17. PubMed ID: 30159416
[TBL] [Abstract][Full Text] [Related]
2. Relations between approved platinum drugs and non-coding RNAs in mesothelioma.
Biersack B
Noncoding RNA Res; 2018 Dec; 3(4):161-173. PubMed ID: 30809599
[TBL] [Abstract][Full Text] [Related]
3. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Pang SK; So WK; Ho YP; Au-Yeung CF
Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
[TBL] [Abstract][Full Text] [Related]
4. The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma.
Lu E; Gareev I; Yuan C; Liang Y; Sun J; Chen X; Beylerli O; Sufianov A; Zhao S; Yang G
Curr Pharm Des; 2022; 28(23):1863-1869. PubMed ID: 35674307
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
6. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin: a review of preclinical and clinical studies.
Raymond E; Chaney SG; Taamma A; Cvitkovic E
Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
[TBL] [Abstract][Full Text] [Related]
8. Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl)cyclobutane-1,1-Dicarboxylate as a leaving ligand.
Liu F; Yang C; Li S; Wu X; Xue K; Zhou Y; Liang X; Cheng X; Shi Q; Su W
Eur J Med Chem; 2022 Nov; 242():114673. PubMed ID: 36049275
[TBL] [Abstract][Full Text] [Related]
9. Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin.
Alexander C; Nithyakumar A; Paul MWB; Arockia Samy N
J Biol Inorg Chem; 2018 Jul; 23(5):833-848. PubMed ID: 29934700
[TBL] [Abstract][Full Text] [Related]
10. Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines.
Lange C; Bednarski PJ
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332729
[TBL] [Abstract][Full Text] [Related]
11. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
12. Advancements in the Use of Platinum Complexes as Anticancer Agents.
Sharma R; Singh VJ; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):821-835. PubMed ID: 34353272
[TBL] [Abstract][Full Text] [Related]
13. Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics.
Schoch S; Gajewski S; Rothfuß J; Hartwig A; Köberle B
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32967255
[TBL] [Abstract][Full Text] [Related]
14. Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs.
Hacker MP; Khokhar AR; Brown DB; McCormack JJ; Krakoff IH
Cancer Res; 1985 Oct; 45(10):4748-53. PubMed ID: 4040806
[TBL] [Abstract][Full Text] [Related]
15. Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma.
Biersack B
Noncoding RNA Res; 2018 Dec; 3(4):213-225. PubMed ID: 30809600
[TBL] [Abstract][Full Text] [Related]
16. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
17. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane.
Yu CW; Li KK; Pang SK; Au-Yeung SC; Ho YP
Bioorg Med Chem Lett; 2006 Mar; 16(6):1686-91. PubMed ID: 16386904
[TBL] [Abstract][Full Text] [Related]
18. The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis.
Kiyonari S; Iimori M; Matsuoka K; Watanabe S; Morikawa-Ichinose T; Miura D; Niimi S; Saeki H; Tokunaga E; Oki E; Morita M; Kadomatsu K; Maehara Y; Kitao H
Mol Cancer Ther; 2015 Oct; 14(10):2332-42. PubMed ID: 26208523
[TBL] [Abstract][Full Text] [Related]
19. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).
Chaney S
Int J Oncol; 1995 Jun; 6(6):1291-305. PubMed ID: 21556672
[TBL] [Abstract][Full Text] [Related]
20. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.
Wang Y; Wang Y; Qin Z; Cai S; Yu L; Hu H; Zeng S
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):291-306. PubMed ID: 33544643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]